Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.048 AUD | +4.35% | +23.08% | +118.18% |
Apr. 09 | Anatara Lifesciences Begins Recruitment for Irritable Bowel Syndrome Stage Two Trial | MT |
Feb. 28 | Anatara Lifesciences Ltd Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Brookes
CEO | Chief Executive Officer | 63 | 19-01-22 |
John Michailidis
COO | Chief Operating Officer | - | - |
Simon Erskine
PRN | Corporate Officer/Principal | - | 21-12-05 |
Stephen Denaro
SEC | Corporate Secretary | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David Brookes
CEO | Chief Executive Officer | 63 | 19-01-22 |
John Michailidis
COO | Chief Operating Officer | - | - |
Nicholas Haslam
BRD | Director/Board Member | - | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 167,893,727 | 107,260,729 ( 63.89 %) | 0 | 63.89 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+118.18% | 5.26M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- ANR Stock
- Company Anatara Lifesciences Ltd